Phosphate Therapeutics
Development of mineral-derived hospital pharmaceuticals.
Launch date
Market cap
CAD58.4m
Enterprise valuation
CAD75m (Public information from Sep 2024)
Share price
£0.03992 STX.L
Company register number 07618820
London England (HQ)
Financials
Estimates*
| GBP | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 10.4m | 1.5m | 4.5m | 12.4m | 36.3m | 71.1m | - |
| % growth | 1345 % | (85 %) | 194 % | 177 % | 194 % | 96 % | - |
| EBITDA | <1m | (17.3m) | (22.6m) | (22.9m) | (10.8m) | 10.1m | - |
| % EBITDA margin | 8 % | (1142 %) | (506 %) | (186 %) | (30 %) | 14 % | - |
| Profit | (2.6m) | (19.3m) | (40.4m) | (25.2m) | (13.3m) | 11.8m | - |
| % profit margin | (25 %) | (1273 %) | (905 %) | (204 %) | (37 %) | 17 % | - |
| EV / revenue | 6.9x | 55.4x | 4.1x | 4.7x | 1.6x | 0.8x | - |
| EV / EBITDA | 87.6x | -4.8x | -0.8x | -2.5x | -5.5x | 5.5x | - |
| R&D budget | 2.6m | <1m | 1.1m | 1.4m | - | - | - |
| R&D % of revenue | 25 % | 38 % | 24 % | 11 % | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
€10.5m | Early VC | ||
| N/A | £32.5m | IPO | |
| Total Funding | CAD15.8m | ||
Related Content
Recent News about Phosphate Therapeutics
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.